Trimodal therapy for prostate cancer
DOI: 10.22591/magyurol.2023.2.szantoa.88
Authors:
Szántó Árpád dr., Damásdi Miklós dr.
Pécsi Tudományegyetem, Klinikai Központ, Urológiai Klinika, Pécs (igazgató: Szántó Árpád dr.)
Summary
The use of trimodal therapy (multimodality treatments) in prostate cancer is a new therapeutic concept that involves the previously used treatment options (radical prostatectomy, EBRT, BT, ADT, ARTA) combination. The combined therapy’s benefit is to prevent the local spread of the disease and early biochemical relapse caused by loco-regional micrometastases. The trimodal treatments do not have a high level of evidence recommendation in the available international guidelines, but based on the increasing number of publications, combination treatments may be more beneficial in the evaluation of certain oncological outcomes. In this summary, the combined trimodal treatment options is analysed, focusing on their indications, and presenting their oncological effects and the patients’ quality of life.